Biohaven Pharma

220 articles with Biohaven Pharma

• 

  Clinical Catch-Up: March 8-12

  3/15/2021

  It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson's disease, Alzheimer's, HIV and more.

• Biohaven's NURTEC® ODT Approved In United Arab Emirates For Acute Treatment Of Migraine

  3/11/2021

  - NURTEC ODT obtained market authorization in the United Arab Emirates, along with the recent approval in Israel - NURTEC ODT is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in a fast-acting orally disintegrating tablet (ODT)

• Biohaven Announces Completion Of 50% Enrollment Ahead Of Timelines In Verdiperstat Pivotal HEALEY ALS Platform Trial At Massachusetts General Hospital

  3/10/2021

  Biohaven's verdiperstat was selected as one of the first three drug candidates to be studied in the innovative HEALEY ALS Platform Trial at MGH

• Biohaven Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Developments

  3/1/2021

  Biohaven reports NURTEC® ODT (rimegepant) net product revenues for the fourth quarter of 2020 were $35.1 million, representing a 98% increase compared to the third quarter of 2020, and $63.6 million for calendar year 2020 following U.S. commercial launch in March of 2020 - Exceeded market expectations with robust growth of NURTEC ODT totaling over 337,000 prescriptions in 2020 and over 24,000 unique prescribers

• Biohaven's BHV-1200, A Multimodal Antibody Therapy Enhancer (MATE), Demonstrates Effective Neutralization Of Multiple Strains Of COVID-19

  2/22/2021

  -Biohaven's proprietary MATE™ conjugation platform has been used to generate a new class of antibody-based therapies to target COVID-19 -BHV-1200, a COVID-19 targeting MATE compound, recently completed in vitro testing that demonstrated activity against SARS-CoV-2 wild-type as well as mutants associated with reduced susceptibility to therapeutic monoclonal antibodies and emerging strains

• Biohaven Provides Update On ESG Practices

  2/8/2021

  Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven"), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates today announced the advancement of several important steps that underscore the company's commitment to sound Environmental, Social and Governance ("ESG")

• Biohaven Announces Preliminary 4Q2020 Net Product Revenue For NURTEC® ODT

  1/25/2021

   Biohaven Pharmaceutical Holding Company Ltd.today announced preliminary net product revenue of NURTEC ODT (rimegepant) for the fourth quarter of 2020. 

• 

  Clinical Catch-Up: January 18-22

  1/25/2021

  With a presidential inauguration and a federal holiday, it wasn’t an enormously busy week for clinical trial news, but there was a fair amount, nonetheless. Read on to see.

• Biohaven Signs Cody Ware as Driver for Nurtec® ODT Chevrolet for the 2021 NASCAR Cup Series Season

  1/18/2021

  Biohaven Pharmaceuticals announced that Cody Ware will pilot the Nurtec® ODT #51 Chevrolet Camaro for Rick Ware Racing during the 2021 NASCAR Cup Series season.

• Biohaven's Nurtec® ODT Partners with Rick Ware Racing for 24 Hours of Daytona Entry

  1/5/2021

  Biohaven Pharmaceuticals announced that Nurtec® ODT will be the primary sponsor on the #51 Ligier JS P217 entry into the LMP2 class of the 2021 24 Hours of Daytona.

• Sosei Heptares and Biohaven Enter Global Collaboration and License Agreement to Advance Novel Small-Molecule CGRP Antagonist Portfolio

  12/1/2020

  Sosei Group Corporation announces it has entered into a global collaboration and license agreement with Biohaven Pharmaceutical Holding Company Ltd..

• Biohaven Pharmaceuticals And Weill Cornell Medicine Collaborate To Initiate Proof Of Concept Trial With CGRP Receptor Antagonist In Plaque Psoriasis

  11/16/2020

  Weill Cornell Medicine's Dr. Richard Granstein, M.D., Chairman of Dermatology, will collaborate with Biohaven to study a Calcitonin Gene-Related Peptide (CGRP) receptor-antagonist in plaque psoriasis

• Biohaven Pharmaceuticals Inaugural Partner Of National Ataxia Foundation's Drug Development Collaborative

  11/11/2020

  - National Ataxia Foundation (NAF) Drug Development Collaborative to cultivate resources that facilitate research and development of new potential treatments for Ataxia, a set of severe and debilitating neurodegenerative diseases - Biohaven Pharmaceuticals, the first industry sponsor of the Collaborative, is currently conducting a Phase 3 clinical trial of troriluzole for Spinocerebellar Ataxia (SCA)

• Biohaven Reports Third Quarter 2020 Financial Results and Recent Business Developments

  11/9/2020

  $60.0 million Series A funding completed by Asia-Pacific subsidiary, BioShin to bring NURTEC™ ODT to an estimated 80 million migraine sufferers in China

• U.S. FDA Accepts Biohaven's Supplemental New Drug Application (sNDA) Of NURTEC™ ODT For The Preventive Treatment Of Migraine

  10/14/2020

  Acceptance marks critical milestone in Biohaven's efforts to develop NURTEC ODT as a unique dual therapy for both the preventive and acute treatment of migraine NURTEC ODT 75 mg has been shown in placebo-controlled trials to return patients to normal functioning within 60 minutes when used in the acute treatment of migraine and has also been shown to reduce monthly migraine days at the same 75 mg dose administered every other day for preventive treatment

• BioShin, Biohaven's Asia-Pacific Subsidiary, Raises $60M in Series A Funding to Advance Neuroscience Pipeline in Asia-Pacific Region

  9/28/2020

  Initiating NURTEC ODT Phase 3 study for acute migraine in China and Korea, and China registrational study of troriluzole in Spinocerebellar Ataxia in 4Q20

• 

  Clinical Catch-Up: September 7-11

  9/14/2020

  It was a busy week for clinical trial updates. Here’s a look.

• Biohaven's Oral Zavegepant, A Third Generation CGRP Receptor Antagonist, Receives Authorization To Proceed From FDA And Achieves First In Human Dosing

  9/10/2020

  - Investigational New Drug (IND) application was authorized to proceed by the US FDA for human dosing with oral zavegepant - Biohaven achieved first in human dosing with oral zavegepant to assess the safety and pharmacokinetic profile - Zavegepant is a third generation, high affinity, selective and structurally unique, small molecule CGRP receptor antagonist in development for both migraine and non-migraine indications including COVID-19 associated lung inflammation

• Biohaven Reports Second Quarter 2020 Financial Results And Recent Business Developments

  8/10/2020

  - NURTEC™ ODT (rimegepant) achieved net revenues of $9.7M for the second quarter of 2020 and now NBRx market leader with 52.6% of share - Company well-capitalized with recent non-dilutive financing of up to $950M from Sixth Street term loan and Royalty Pharma funding agreement - Remains on timelines for NURTEC ODT sNDA filing for prevention of migraine in the coming months; additionally, completion of troriluzole Alzheimer's Disease Phase 2/3 trial in 4Q2020, and topline resu

• Biohaven Announces up to $500 Million Non-Dilutive Term Loan with Sixth Street

  8/7/2020

   Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven" or the "Company") announced that it entered into a $500 million non-dilutive term loan financing facility with Six